

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. SSM Health St. Clare Hospital-Fenton</p>	<p>In accordance with letter dated June 22, 2016</p>	<p>4. Expiration Date: October 31, 2025</p>	
<p>2. 1015 Bowles Avenue Fenton, MO 63026</p>	<p>3. License number: 24-11858-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02368 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iridium-192 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Best Medical International, Inc., Model 81-01)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. As Needed</p> <p>D. 1 curie total</p>	<p>9. Authorized use</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-11858-01

Docket or Reference Number
030-02368

Amendment No. 58

6. Byproduct, source,
and/or special nuclear
material

E. Iodine-125 permitted by
10 CFR 35.400

F. Palladium-103 permitted
by 10 CFR 35.400

7. Chemical and/or physical form

E. Sealed Sources (Bard
Brachtherapy, Inc., Model STM
1251; Best Medical
International, Inc., Model 2301 to
2316; Core Oncology, Inc.,
Model I-125 SL (ProstaSeed);
Implant Sciences Corporation,
Model 3500 (I-Plant);
International Brachytherapy
S.A., Model 1251L; IsoAid, LLC.,
Model IAI-125A (Advantage);
Medi-Physics, Inc., Model 6711
(OncoSeed); North American
Scientific, Inc., Model 3631;
Syncor, Model BT-125-1;
Theragenics I-Seed, Model
AgX100)

F. Sealed Sources (Best Medical
International, Inc., Model 2331
and 2335; Core Oncology, Inc.,
Model 103 SL; International
Brachytherapy S.A., Model
1031L; IsoAid, LLC., Model
IAPd-103A (Advantage Pd-103);
Medi-Physics, Inc., Model 6733
(EchoSeed); North American
Scientific, Inc., Model MED
3633; Theragenics Corporation,
Model TheraSeed 200)

8. Maximum amount that licensee
may possess at any one time
under this license

E. 1 curie total

F. 1 curie total

9. Authorized use

E. Any manual brachytherapy procedure
permitted by 10 CFR 35.400.

F. Any manual brachytherapy procedure
permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
24-11858-01

Docket or Reference Number
030-02368

Amendment No. 58


CONDITIONS

10. Licensed material listed in above. may be used and stored at 1015 Bowles Avenue, Fenton, Missouri.
11. The Radiation Safety Officer for this license is Andre Strzembosz, M.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|---|
| Ronald Palmer, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| Andre Strzembosz, M.D. | 10 CFR 35.100, 35.200 and 35.300. |
| Karen J. Baranski, M.D. | 10 CFR 35.100 and 35.200. |
| Thomas P. Bocchini, M.D. | 10 CFR 35.100 and 35.200. |
| Robert J. Gresick, M.D. | 10 CFR 35.100 and 35.200. |
| Megan Maine Gau, M.D. | 10 CFR 35.100 and 35.200. |
| Robert Swanson, M.D. | 10 CFR 35.300 and 35.400 (limited to Iodine-125 and Palladium-103). |
| John Bedwinek, M.D. | 10 CFR 35.300 and 35.400. |
| David Morris, M.D. | 10 CFR 35.300 and 35.400. |
| John Joseph Stephens, M.D. | 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131) |
| Thomas M. Schroyer, M.D. | 10 CFR 35.100 and 35.200. |
| Rebecca J. Mueller, M.D. | 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131). |
| Robert M. Fischer, M.D. | 10 CFR 35.100 and 35.200. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-11858-01Docket or Reference Number
030-02368

Amendment No. 58

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 20, 2015 (ML 15118A911)
 - B. Letter dated September 29, 2015 (ML 15273A058)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 9, 2016By: Toy L. Simmons
Region III